Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Terminal disease

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    684 result(s) found for: Terminal disease. Displaying page 7 of 35.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    EudraCT Number: 2021-000868-30 Sponsor Protocol Number: NL76215.042.20 Start Date*: 2021-02-17
    Sponsor Name:RECOVAC consortium
    Full Title: The immune-response and safety of COVID-19 vaccination in patients with chronic kidney disease, on dialysis, or living with a kidney transplant
    Medical condition: COVID-19 is associated with increased morbidity and mortality in kidney transplant recipients (KTR) and patients with chronic kidneydisease (CKD). Therefore, potential efficacious SARS-CoV-2 vaccin...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10023438 Kidney transplant LLT
    20.0 10042613 - Surgical and medical procedures 10061105 Dialysis PT
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    23.1 10042613 - Surgical and medical procedures 10084465 COVID-19 vaccination LLT
    23.1 100000004862 10084401 COVID-19 respiratory infection LLT
    23.1 10042613 - Surgical and medical procedures 10084464 COVID-19 immunization LLT
    23.0 100000004862 10084272 SARS-CoV-2 infection LLT
    23.0 10042613 - Surgical and medical procedures 10084462 SARS-CoV-2 vaccination LLT
    23.0 10042613 - Surgical and medical procedures 10084463 SARS-CoV-2 immunisation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2010-019439-37 Sponsor Protocol Number: M10-149 Start Date*: 2010-10-18
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 3, Prospective, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Paricalcitol Capsules in Decreasing Serum Intact Para...
    Medical condition: Moderate to Severe Chronic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004857 10064848 Chronic kidney disease LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) PT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-004050-29 Sponsor Protocol Number: PHI116581 Start Date*: 2013-01-07
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A four-week Phase IIa, randomized, double-blind, placebocontrolled, parallel-group, multi-center study to evaluate the safety, efficacy and pharmacokinetics of GSK1278863 in subjects with anemia as...
    Medical condition: Anemia associated with chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004857 10064848 Chronic kidney disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-001197-34 Sponsor Protocol Number: 200942 Start Date*: 2014-11-05
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A repeat-dose, open-label, parallel-group study to assess the pharmacokinetics of GSK1278863 and metabolites in subjects with End Stage Renal Disease undergoing peritoneal dialysis.
    Medical condition: Anemia associated with chronic kidney disease (CKD)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004857 10064848 Chronic kidney disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-003229-47 Sponsor Protocol Number: KEEP-ON Start Date*: 2022-01-12
    Sponsor Name:Instituto de Investigación Sanitaria INCLIVA
    Full Title: Phase III, multicenter, open-label, randomized clinical trial to evaluate efficacy of Sodium Zirconium Cyclosilicate (Lokelma) compared to standard of care to manage hyperkalemia in patients with c...
    Medical condition: Hyperkalemia in patients with chronic kidney disease (CKD) and heart failure history
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10020647 Hyperkalemia LLT
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    20.0 100000004849 10019285 Heart failure, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-004049-34 Sponsor Protocol Number: PHI116582 Start Date*: 2013-01-07
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A four-week, Phase IIa, randomized, active-controlled, parallel-group, multi-center study to evaluate the safety, efficacy and pharmacokinetics of switching subjects from a stable dose of recombina...
    Medical condition: Anaemia associated with chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004857 10064848 Chronic kidney disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NO (Completed) SE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2015-001925-18 Sponsor Protocol Number: GED-0301-CD-002 Start Date*: 2016-02-24
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 3, randomized, double-blind, placebo-controlled, multicenter study to investigate the efficacy and safety of mongersen (GED-0301) for the treatment of subjects with active Crohn’s disease.
    Medical condition: Active Crohn's disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000016693 10021315 Ileitis terminal LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) SE (Completed) SK (Completed) LV (Prematurely Ended) EE (Prematurely Ended) DE (Prematurely Ended) PT (Prematurely Ended) HU (Completed) CZ (Prematurely Ended) AT (Prematurely Ended) ES (Prematurely Ended) DK (Prematurely Ended) BE (Completed) NO (Completed) BG (Prematurely Ended) GR (Completed) HR (Prematurely Ended) FI (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-005434-12 Sponsor Protocol Number: Nephropaed-PD-01/B Start Date*: 2008-07-02
    Sponsor Name:Universitaetsklinikum Erlangen
    Full Title: Randomized, multicenter cross-over study investigating the effect of bicarbonate-based solutions (Physioneal 35 vs. 40) on protein metabolism in children and adolescents on chronic peritoneal dialysis
    Medical condition: Pediatric and adolescent patients with end-stage renal failure undergoing chronic peritoneal dialysis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064848 Chronic kidney disease LLT
    9.1 10064116 Continuous ambulatory peritoneal dialysis LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-009427-11 Sponsor Protocol Number: PD-NL-04-EU Start Date*: 2010-10-13
    Sponsor Name:Fresenius Medical Care Deutschland GmbH
    Full Title: Efecto de la solución de diálisis peritoneal balance sobre la membrana peritoneal de pacientes tratados con diálisis peritoneal automatizada (DPA) (The effect of balance peritoneal dialysis solutio...
    Medical condition: Pacientes con enfermedad renal crónica tratados con diálisis peritoneal
    Disease: Version SOC Term Classification Code Term Level
    9.1 10014646 End stage renal disease (ESRD) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2022-002892-12 Sponsor Protocol Number: CHUB-VASO-IRC Start Date*: 2022-09-13
    Sponsor Name:CHU Brugmann
    Full Title: Comparison of the efficacy of ephedrine versus norepinephrine in the treatment of hypotension occurring after induction of general anesthesia in patients with chronic renal failure: randomized doub...
    Medical condition: Hypotension occurring post-induction of general anesthesia in patients with chronic renal failure during elective surgery.
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10009119 Chronic renal failure LLT
    20.0 10047065 - Vascular disorders 10021097 Hypotension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2008-001335-36 Sponsor Protocol Number: 2007.495/38 Start Date*: 2008-05-15
    Sponsor Name:HOSPICES CIVILS DE LYON
    Full Title: Evaluation de la fonction rénale après introduction de l’évérolimus chez le transplanté cardiaque présentant une insuffisance rénale chronique : étude multicentrique, randomisée en ouvert
    Medical condition: Transplanté cardiaque présentant une insuffisance rénale chronique
    Disease: Version SOC Term Classification Code Term Level
    9.1 10007611 Cardiac transplant LLT
    9.1 10009119 Chronic renal failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-003788-23 Sponsor Protocol Number: ACE-011-REN-002 Start Date*: 2013-10-07
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 2 Multicenter, Randomized, Open Label, Multiple Dose Study of Intravenous and Subcutaneous Administration of Sotatercept (ACE-011) in Subjects with End-Stage Kidney Disease on Hemodialysis ...
    Medical condition: End-stage kidney disease (ESKD) who are on hemodialysis and will be switched from their current stable treatment with erythropoiesisstimulating agent (ESA) to sotatercept.
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004857 10064848 Chronic kidney disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) PT (Completed) GB (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2017-002971-24 Sponsor Protocol Number: 1245-0137 Start Date*: 2018-10-29
    Sponsor Name:Boehringer Ingelheim International GmbH
    Full Title: A multicentre international randomized parallel group double-blind placebo-controlled clinical trial of EMPAgliflozin once daily to assess cardio-renal outcomes in patients with chronic KIDNEY disease
    Medical condition: Chronic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-006994-48 Sponsor Protocol Number: EMPATICC-INCOR1 Start Date*: 2022-07-25
    Sponsor Name:Universitätsklinikum Essen
    Full Title: Empower the Heart of Patients with Terminal Cancer using Cardiac Medicines Trial
    Medical condition: Patients with terminal cancer in palliative care
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10059513 Palliative care PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-004496-40 Sponsor Protocol Number: I5V-MC-TGAB Start Date*: 2013-03-01
    Sponsor Name:Eli Lilly and Company
    Full Title: Study of the Safety and Efficacy of LY3016859 after Multiple Intravenous Dosing in Diabetic Nephropathy Patients
    Medical condition: Chronic kidney disease associated with Diabetic nephropathy
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004857 10064848 Chronic kidney disease LLT
    16.1 100000004857 10012678 Diabetic nephropathy NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-004058-28 Sponsor Protocol Number: HN017/HBV-003 Start Date*: 2006-02-02
    Sponsor Name:Henogen
    Full Title: A phase III multicentric, multinational, controlled, randomised, open study comparing the immunogenicity, reactogenicity and safety of Henogen’s new adjuvanted hepatitis B vaccine, HB-AS02V, to th...
    Medical condition: Female and male pre-dialysis, peritoneal dialysis and haemodialysis patients with documented evidence of nonresponse to previous hepatitis B vaccination [non-response to previous hepatitis B vaccin...
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) BE (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005058-70 Sponsor Protocol Number: APO-EPO-03 Start Date*: 2013-02-27
    Sponsor Name:APOTEX Inc.
    Full Title: A phase III, randomized, open-label, active-controlled, multicenter, correction phase study of the efficacy, safety, pharmacokinetics, and pharmacodynamics of APO-EPO (epoetin alfa) as compared to ...
    Medical condition: Treatment of anemia due to chronic kidney disease in patients not yet on hemodialysis
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004857 10064848 Chronic kidney disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) SK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-002878-50 Sponsor Protocol Number: NN9535-4321 Start Date*: 2019-04-02
    Sponsor Name:Novo Nordisk A/S
    Full Title: Effect of semaglutide versus placebo on the progression of renal impairment in subjects with type 2 diabetes and chronic kidney disease
    Medical condition: Diabetes Mellitus, Type 2 Chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) HU (Completed) NL (Completed) SK (Completed) BG (Completed) DE (Completed) ES (Ongoing) FR (Completed) PL (Completed) BE (Completed) GR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-000828-19 Sponsor Protocol Number: NN9535-4662 Start Date*: 2021-01-25
    Sponsor Name:Novo Nordisk A/S
    Full Title: Renal mode of action of semaglutide in patients with type 2 diabetes and chronic kidney disease
    Medical condition: Diabetes Mellitus, Type 2 Chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) FR (Completed) IT (Completed) ES (Ongoing) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-004499-35 Sponsor Protocol Number: 20040218 Start Date*: 2005-03-14
    Sponsor Name:Amgen Limited
    Full Title: A Study to Evaluate the Efficacy of Converting from Intravenous or Subcutaneous rHuEPO to Intravenous Darbepoetin Alfa in Subjects with Chronic Kidney Disease Receiving Haemodialysis
    Medical condition: Anemia caused by chronic kidney didease.
    Disease: Version SOC Term Classification Code Term Level
    6.1 10038444 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 04 05:11:44 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA